USPTO Examiner KELLY ROBERT M - Art Unit 1638

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19200761Circular RNA CompositionsMay 2025November 2025Allow610YesNo
19097114AAV CAPSID VARIANTS AND USES THEREOFApril 2025June 2025Allow310NoNo
19046845METHODS AND MEANS FOR THE PREVENTION AND/OR TREATMENT OF HEMOPHILIC ARTHROPATHY IN HEMOPHILIAFebruary 2025October 2025Allow820YesNo
18900968METHOD FOR EFFICIENTLY INFECTING HUMAN NATURAL KILLER CELLS AND OTHER IMMUNE CELLS WITH PSEUDOVIRUSSeptember 2024August 2025Allow1020YesNo
18886134LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOFSeptember 2024December 2024Allow310NoNo
18821057DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDSAugust 2024February 2025Allow610NoNo
18820609DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDSAugust 2024February 2025Allow510NoNo
18821068DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDSAugust 2024February 2025Allow610NoNo
18820652DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDSAugust 2024March 2025Allow710YesNo
18796740GENE-REGULATING COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPYAugust 2024December 2024Allow410NoNo
18777787COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING IMPAIRMENT IN A HUMAN SUBJECTJuly 2024February 2025Allow710NoNo
18777187COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING IMPAIRMENT IN A HUMAN SUBJECTJuly 2024January 2025Allow610NoNo
18765147COMPOSITIONS AND METHODS FOR DELIVERING MOLECULESJuly 2024September 2025Allow1521NoNo
18757141AAV CAPSID VARIANTS AND USES THEREOFJune 2024March 2025Allow811NoNo
18649317RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USEApril 2024November 2024Allow610NoNo
18620748Use of CD2/5/7 Knock-Out Anti-CD2/5/7 Chimeric Antigen Receptor T cells Against T Cell Lymphomas and LeukemiasMarch 2024October 2024Allow720YesNo
18583191CELLULAR REPROGRAMMING TO REVERSE AGING AND PROMOTE ORGAN AND TISSUE REGENERATIONFebruary 2024January 2026Allow2340YesNo
18583147CELLULAR REPROGRAMMING TO REVERSE AGING AND PROMOTE ORGAN AND TISSUE REGENERATIONFebruary 2024July 2025Allow1620YesNo
18413653LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOFJanuary 2024June 2024Allow510NoNo
18508998METHODS AND MEANS FOR THE PREVENTION AND/OR TREATMENT OF HEMOPHILIC ARTHROPATHY IN HEMOPHILIANovember 2023November 2025Abandon2421NoNo
18560539THERAPEUTIC PHARMACEUTICAL COMPOSITION FOR BONE AND SOFT TISSUE TUMORSNovember 2023January 2025Allow1410YesNo
18485178COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING IMPAIRMENT IN A HUMAN SUBJECTOctober 2023May 2024Allow710YesNo
18550503SMART EXOSOMES FOR ACTIVE PDAC TARGETING AND EVADING MONONUCLEAR PHAGOCYTOTIC SYSTEMSeptember 2023May 2024Allow810NoNo
18458744COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING IMPAIRMENT IN A HUMAN SUBJECTAugust 2023January 2024Allow510NoNo
18458752COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING IMPAIRMENT IN A HUMAN SUBJECTAugust 2023May 2024Allow820YesNo
18267340MICE EXPRESSING HUMANIZED FC ALPHA RECEPTORSJune 2023March 2026Allow3310YesNo
18318566CELLULAR REPROGRAMMING TO REVERSE AGING AND PROMOTE ORGAN AND TISSUE REGENERATIONMay 2023July 2024Allow1450YesNo
18295152LIPID NANOPARTICLE COMPOSITIONS AND METHODS FOR MRNA DELIVERYApril 2023December 2023Allow810YesNo
18295150LIPID NANOPARTICLE COMPOSITIONS AND METHODS FOR MRNA DELIVERYApril 2023December 2023Allow810YesNo
18295159LIPID NANOPARTICLE COMPOSITIONS AND METHODS FOR MRNA DELIVERYApril 2023December 2023Allow810YesNo
18185656GENE THERAPY VECTOR WITH MINIMIZING RECOMBINATION, RECOMBINANT RETROVIRUS COMPRISING THE VECTOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE RECOMBINANT RETROVIRUSMarch 2023February 2024Allow1120YesNo
18017470Galectin-9 Specific Binding Agents for Use in Treating CancerJanuary 2023February 2026Allow3720NoNo
18157633FASL-ENGINEERED BIOMATERIALS WITH IMMUNOMODULATORY FUNCTIONJanuary 2023March 2026Allow3810NoNo
18154742METHODS OF USING ZSCAN4 FOR REJUVENATING HUMAN CELLSJanuary 2023August 2025Allow3110YesNo
18149414SOMATOSTATIN RECEPTOR-BASED CANCER THERAPYJanuary 2023March 2026Allow3810YesNo
18084733METHODS FOR MAKING T CELL COMPOSITIONSDecember 2022February 2026Allow3710NoNo
18065580GENE-REGULATING COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPYDecember 2022May 2024Allow1730YesNo
18001542MULTIFUNCTIONAL IMMUNOTHERAPEUTIC MONOCLONAL ANTIBODY COMPLEXES AND CONJUGATESDecember 2022December 2025Allow3610NoNo
18075940Nanoparticle Modification of Human Adipose-Derived Mesenchymal Stem Cells for Treating Brain Cancer and Other Neurological DiseasesDecember 2022January 2026Allow3810NoNo
17925883Compositions and Methods for Treating Cancer Expressing CD90 and CD326November 2022January 2026Allow3820NoNo
17988824LIPID PARTICLES FOR NUCLEIC ACID DELIVERY AND CLINICAL APPLICATIONS OF SAMENovember 2022January 2026Allow3810NoNo
17924964METHODS OF TREATING CANCER USING A COMBINATION OF ANTI-CD30 ANTIBODY-DRUG CONJUGATESNovember 2022March 2026Abandon4010NoNo
17929165RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USESeptember 2022February 2024Allow1830YesNo
17820694ONCOLYTIC VIRAL VECTORS AND USES THEREOFAugust 2022December 2025Abandon4010NoNo
17819909RESTIMULATION OF CRYOPRESERVED TUMOR INFILTRATING LYMPHOCYTESAugust 2022March 2023Allow720YesNo
17819214RESTIMULATION OF CRYOPRESERVED TUMOR INFILTRATING LYMPHOCYTESAugust 2022January 2024Allow1820YesNo
17819219RESTIMULATION OF CRYOPRESERVED TUMOR INFILTRATING LYMPHOCYTESAugust 2022January 2024Allow1820NoNo
17884808Methods of Combining the Detection of Biomolecules Into a Single Assay Using Fluorescent In Situ SequencingAugust 2022October 2025Allow3910YesNo
17797681ONCOLYTIC VIRUS COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCERAugust 2022January 2026Allow4220NoNo
17759083COMPOUNDS AND CONJUGATES THEREOFJuly 2022January 2026Abandon4210NoNo
17812425VECTOR AND METHOD FOR TREATING BIETTI'S CRYSTALLINE DYSTROPHYJuly 2022April 2024Allow2230NoNo
17812322GENE THERAPY FOR TREATING WILSON'S DISEASEJuly 2022July 2025Allow3610NoNo
17856655COMPOSITIONS AND METHODS FOR NANOPOLYMER-BASED NUCLEIC ACID DELIVERYJuly 2022February 2026Abandon4410NoNo
17855584METHODS OF USING ZSCAN4 FOR REJUVENATING HUMAN CELLSJune 2022July 2025Allow3710NoNo
17851887RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USEJune 2022January 2026Allow4321NoNo
17808873ENCAPSULATION AND CARDIAC DIFFERENTIATION OF hiPSCs IN 3D PEG-FIBRINOGEN HYDROGELSJune 2022July 2025Allow3610NoNo
17847291AAV VECTORS ENCODING NF1 AND USES THEREOFJune 2022September 2025Allow3911NoNo
17836571PROCESSES AND SYSTEMS FOR PREPARING CELLULAR OR VIRAL MEMBRANES AND NANOPARTICLESJune 2022September 2025Allow3920NoNo
17835668METABOLIC THERAPY FOR OXIDATIVE STRESS IN THE BRAIN THROUGH TARGETED NEURONAL CATABOLISM OF N-ACETYL-ASPARTIC ACIDJune 2022July 2025Allow3720YesNo
17832961GENE THERAPY FOR TREATING PHENYLKETONURIAJune 2022October 2025Allow4120NoNo
17832196LIPID NANOPARTICLE COMPOSITIONS AND METHODS FOR MRNA DELIVERYJune 2022February 2024Allow2040YesNo
17830102MRNA THERAPY FOR PHENYLKETONURIAJune 2022August 2025Allow3910YesNo
17779812APOE GENE THERAPYMay 2022December 2025Allow4311NoNo
17751052PROCESSES AND SYSTEMS FOR PREPARING CELLULAR OR VIRAL MEMBRANES AND NANOPARTICLESMay 2022July 2025Allow3811NoNo
17664622COMPOSITIONS AND METHODS FOR TREATING CEP290-ASSOCIATED DISEASEMay 2022September 2025Abandon4001NoNo
17743813COMPOSITIONS AND METHODS FOR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY WITH NADH DEHYDROGENASE PROTEINSMay 2022September 2025Abandon4001NoNo
17661207REGULATABLE CHIMERIC ANTIGEN RECEPTORApril 2022July 2025Abandon3901NoNo
17707725GENE-REGULATING COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPYMarch 2022June 2024Allow2710NoNo
17697841METHODS FOR DISTRIBUTING HIGH LEVELS OF THERAPEUTIC AGENT THROUGHOUT THE CORTEX TO TREAT NEUROLOGICAL DISORDERSMarch 2022March 2025Allow3610NoNo
17691518Compositions Comprising Citrate and Applications ThereofMarch 2022July 2024Allow2811NoNo
17688782CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING LEBER'S CONGENITAL AMAUROSIS 10 (LCA10)March 2022October 2024Allow3110NoNo
17576550CRISSCROSS COOPERATIVE SELF-ASSEMBLYJanuary 2022February 2025Allow3710YesNo
17627165RECOMBINANTLY-MODIFIED ADENO-ASSOCIATED VIRUS (RAAV) HAVING IMPROVED PACKAGING EFFICIENCYJanuary 2022July 2024Allow3010NoNo
17573442ANTI-ARRHYTHMICITY AGENTSJanuary 2022March 2025Allow3810NoNo
17556847COMPOSITIONS AND METHODS FOR ENHANCED GENE EXPRESSION IN CONE CELLSDecember 2021December 2024Allow3630NoNo
17555233DYSTROPHIN R16/R17 SYNTROPHIN PDZ FUSION PROTEINSDecember 2021March 2025Allow3911YesNo
17619178PROTEIN-BASED RESINS FOR ADDITIVE MANUFACTURINGDecember 2021August 2024Allow3211NoNo
17546183DESIGN OF BACTERIOPHAGE-BASED ARTIFICIAL VIRUSES FOR HUMAN GENOME REMODELINGDecember 2021November 2024Allow3510NoNo
17547031METHODS AND COMPOSITIONS FOR INCREASING SIALIC ACID PRODUCTION AND TREATING SIALIC RELATED DISEASE CONDITIONSDecember 2021January 2026Abandon5040YesNo
17527766BRANCHED RECEPTOR BINDING MULTI-SUBUNIT PROTEIN COMPLEXES FOR USE IN BACTERIAL DELIVERY VEHICLESNovember 2021May 2025Abandon4201NoNo
17522284IMMUNOLOGIC EFFECTOR CELL OF TARGETED CLD18A2, AND PREPARATION METHOD AND USE THEREOFNovember 2021June 2024Allow3110NoNo
17520113RNA NANOSTRUCTURES AND METHODS OF MAKING AND USING RNA NANOSTRUCTURESNovember 2021August 2025Allow4520NoNo
17450544COMPOSITIONS AND METHODS FOR TREATING CEP290-ASSOCIATED DISEASEOctober 2021November 2024Abandon3710NoNo
17498168MINIMALLY INVASIVE CELL TRANSPLANT PROCEDURE TO INDUCE THE DEVELOPMENT OF IN VIVO ORGANOGENESISOctober 2021August 2025Allow4620YesNo
17488542PROKARYOTIC-EUKARYOTIC HYBRID VIRAL VECTOR FOR DELIVERY OF LARGE CARGOS OF GENES AND PROTEINS INTO HUMAN CELLSSeptember 2021April 2024Allow3120NoNo
17459095HIGH THROUGHPUT ASSAY FOR MEASURING ADENOVIRUS REPLICATION KINETICSAugust 2021May 2024Allow3310NoNo
17458083METHODS OF PREPARING AND USING NOVEL STEM CELL COMPOSITIONS AND KITS COMPRISING THE SAMEAugust 2021May 2025Abandon4410NoNo
17412592COMPOSITIONS FOR THE TREATMENT OF DISEASEAugust 2021April 2025Allow4311NoNo
17310783CELL ADHESION COMPOSITION AND CELL ADHESION SUBSTRATEAugust 2021December 2025Abandon5221NoNo
17400467IMMUNE CELL FUNCTIONAugust 2021June 2025Allow4721YesNo
17393362POLYMERIC CARRIER CARGO COMPLEX FOR USE AS AN IMMUNOSTIMULATING AGENT OR AS AN ADJUVANTAugust 2021July 2024Abandon3610NoNo
17391862MATERIALS AND METHODS FOR TREATMENT OF USHER SYNDROME TYPE 2A AND/OR NON-SYNDROMIC AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA (ARRP)August 2021June 2024Allow3510YesNo
17383138GENE THERAPY VECTORS FOR TREATING HEART DISEASEJuly 2021July 2025Allow4841NoNo
17378580NUCLEIC ACID THERAPEUTICS FOR GENETIC DISORDERSJuly 2021April 2025Allow4520YesNo
17369831COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIESJuly 2021December 2024Allow4111NoNo
17367619Microfluidic Delivery Method Utilizing An Electric FieldJuly 2021April 2024Allow3320NoNo
17366708Use of Car and Bite Technology Coupled with an SCFV from an Antibody Against Human Thymidine Kinase 1 to Specifically Target TumorsJuly 2021February 2024Allow3110NoNo
17360578MATERIALS AND METHODS FOR TREATMENT OF USHER SYNDROME TYPE 2AJune 2021September 2024Allow3920NoNo
17355325LINKED PERFUSION TO CONTINUOUS-FLOW STIRRED-TANK REACTOR CELL CULTURE SYSTEMJune 2021September 2024Allow3911NoNo
17350769METHODS FOR EFFICIENT DELIVERY OF THERAPEUTIC MOLECULES IN VITRO AND IN VIVOJune 2021May 2024Allow3510NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KELLY, ROBERT M.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
1
Examiner Affirmed
1
(100.0%)
Examiner Reversed
0
(0.0%)
Reversal Percentile
0.6%
Lower than average

What This Means

With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
27
Allowed After Appeal Filing
5
(18.5%)
Not Allowed After Appeal Filing
22
(81.5%)
Filing Benefit Percentile
22.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 18.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner KELLY, ROBERT M - Prosecution Strategy Guide

Executive Summary

Examiner KELLY, ROBERT M works in Art Unit 1638 and has examined 192 patent applications in our dataset. With an allowance rate of 89.6%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 42 months.

Allowance Patterns

Examiner KELLY, ROBERT M's allowance rate of 89.6% places them in the 72% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.

Office Action Patterns

On average, applications examined by KELLY, ROBERT M receive 2.57 office actions before reaching final disposition. This places the examiner in the 75% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by KELLY, ROBERT M is 42 months. This places the examiner in the 18% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +13.9% benefit to allowance rate for applications examined by KELLY, ROBERT M. This interview benefit is in the 52% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 26.1% of applications are subsequently allowed. This success rate is in the 42% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 52.3% of cases where such amendments are filed. This entry rate is in the 78% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 93% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 95.8% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 91.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 48.3% are granted (fully or in part). This grant rate is in the 44% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 22.9% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 7.0% of allowed cases (in the 85% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.